Benign Prostatic Hyperplasia (BPH) Treatment Market

How Are Product Launches Supporting Benign Prostatic Hyperplasia Treatment Market Growth? The benign prostatic hyperplasia (BPH) treatment market growth will thrive on factors such as the surging geriatric population, growing prevalence of prostate cancer, soaring awareness of prostate cancer and its treatments, rising adoption of minimally invasive procedures, enhancing healthcare infrastructure, and increasing technological advancements in personalized medicine, during the forecast period (2021–2030). According to P&S Intelligence, the benign prostatic hyperplasia (BPH) treatment market revenue will rise from $10 billion in 2020 to $17 billion by 2030. Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/benign-prostatic-hyperplasia-treatment-bph-market/report-sample One of the prominent growth drivers for the market is the soaring geriatric population across the world. According to the World Ageing Population 2020 report, the population of people aged 65 years or above will reach approximately 1.5 billion by 2050. As old people are highly susceptible to diseases such as BPH, market players are undertaking numerous research and development (R&D) activities to treat prostate conditions, particularly in the aging population, thereby fueling the need for additional care. At present, the BPH treatment market is witnessing a trend of product launches and approvals. Surgery is a better option for managing BPH than medication, but patients usually prefer medication over surgeries due to the post-operative damages caused by surgical cuts and burns. However, the advent of minimally invasive surgeries has changed the perception of patients toward surgical procedures. For instance, in August 2020, Teleflex Inc. developed the UroLift enhanced tissue control system to treat BPH patients.